Projects per year
Fingerprint Dive into the research topics where Evanthia Galanis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 26 Similar Profiles
Measles virus
Medicine & Life Sciences
Oncolytic Viruses
Medicine & Life Sciences
Glioblastoma
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Glioma
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Clinical Trials
Medicine & Life Sciences
Oncolytic Virotherapy
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 1976 2021
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer
Kaufmann, S. H., Cliby, W. A., Bible, K. C., Goode, E. L., Galanis, E., Knutson, K. L., Hartmann, L. C., Oberg, A. L., Couch, F. J., Fields, A. P., Haluska, P. R. J., Long, H., Bell, D., Keeney, G., Lengyel, E., Keeney, G., Shridhar, V., Cliby, W. A., Goode, E. L., Peng, K., Hartmann, L. C. & Lingle, W. L.
10/1/08 → 8/31/20
Project: Research project
Ovarian Neoplasms
alvocidib
Registries
Research
Translational Medical Research
P-1: The Role of CHFR in Tumorigenesis and Paclitaxwl-Sensitivity in Breast Cance
Gendler, S. J., Vachon, C. M., Suman, V. J., Ingle, J. N., Lingle, W. L., Couch, F. J., Goetz, M. P., Haluska, P. R. J., Chen, J., Hawse, J. R., Wang, L. M., Visscher, D. W., Galanis, E., Ingle, J. N. & Ingle, J. N.
7/1/05 → 8/31/21
Project: Research project
Breast Neoplasms
Research Personnel
Research
Biostatistics
Translational Medical Research
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers
Project: Research project
Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas
1/1/11 → 12/31/15
Project: Research project
Measles virus
Measles
Glioma
Glioblastoma
Therapeutics
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer
Peng, K., Galanis, E., Galanis, E. & Peng, K.
6/1/09 → 12/31/14
Project: Research project
Measles
Ovarian Neoplasms
Measles virus
Cyclophosphamide
Neoplasms
Research Output 1996 2019
1
Citation
(Scopus)
Advances in multidisciplinary therapy for meningiomas
International Consortium on Meningiomas, Jan 14 2019, In : Neuro-Oncology. 21, 1, p. i18-i31Research output: Contribution to journal › Article
Meningioma
trabectedin
Therapeutics
Radiotherapy
Focal Adhesion Protein-Tyrosine Kinases
A key anti-viral protein, RSAD2/VIPERIN, restricts the release of Measles virus in infected cells
Kurokawa, C., Iankov, I. D. & Galanis, E., Apr 2 2019, In : Virus Research. 263, p. 145-150 6 p.Research output: Contribution to journal › Article
Measles virus
Protein S
Viral Proteins
Methionine
Interferons
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
Galanis, E., Anderson, S. K., Twohy, E. L., Carrero, X. W., Dixon, J. G., Tran, D. D., Jeyapalan, S. A., Anderson, D. M., Kaufmann, T. J., Feathers, R. W., Giannini, C., Buckner, J. C., Anastasiadis, P. Z. & Schiff, D., Jan 1 2019, In : Cancer.Research output: Contribution to journal › Article
Glioblastoma
Placebos
Neoplasms
Therapeutics
National Cancer Institute (U.S.)
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)
Jaeckle, K. A., Anderson, S. K., Twohy, E. L., Dixon, J. G., Giannini, C., Jenkins, R. B., Egorin, M. J., Sarkaria, J. N., Brown, P. D., Flynn, P. J., Schwerkoske, J., Buckner, J. C. & Galanis, E., Jul 1 2019, In : Journal of neuro-oncology. 143, 3, 1 p.Research output: Contribution to journal › Comment/debate
Open Access
Oligodendroglioma
Astrocytoma
Names
Publications
Neoplasms
Interferon signaling predicts response to oncolytic virotherapy
Kurokawa, C. & Galanis, E., Feb 1 2019, In : Oncotarget. 10, 16, p. 1544-1545 2 p.Research output: Contribution to journal › Editorial
Oncolytic Virotherapy
Permissiveness
Measles
Interferons